Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
Bcl-2 family proteins play critical roles in regulating lymphocyte development and maintain homeostasis, and have also been proved to be involved in various cancer types development. However, the role of Bcl-2 in hepatocellular carcinoma (HCC) development has not been clearly studied. Here, we repor...
Main Authors: | Jingye Li, Jinrong Xu, Zhibing Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-08-01
|
Series: | Translational Oncology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S193652332100108X |
Similar Items
-
Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
by: Rocío Jiménez-Guerrero, et al.
Published: (2018-12-01) -
Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma
by: Margarita Espona-Fiedler, et al.
Published: (2022-12-01) -
Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
by: Yun Hua Lee, et al.
Published: (2020-09-01) -
The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
by: Muhammet Ozer, et al.
Published: (2021-12-01) -
Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis
by: Yiding Li, et al.
Published: (2020-05-01)